Menopause Treatment Market Research Report- Global Forecast till 2023

Market Synopsis of Global Menopause treatment Market

Market Scenario

Menopause is termed as the stage of the end of the fertile phase in women which generally occurs at the age of 40 in almost 85% of women. Menopause results in reduced estrogen production and increased gonadotropin, resulting in the cessation of their menstrual cycle and menstrual flow. These physiological changes result in vasomotor symptoms. Vasomotor symptoms are transition between two phases which are peri-menopause and menopause. The major symptoms associated with menopause are as follows:

Hot flashes - Hot flash is the most frequent symptoms of menopause which causes feeling of intensity of heat and excessive sweating.

Formication - Formication in an abnormal skin sensation, itchiness, tingling or burning on the skin and other.

Migraine - Migraine is intense headache which can last from few hours up to many days generally affecting one side of the head. Migraine is a direct effect of hormonal fluctuations of menstrual cycle.

Psychological symptoms associated with menopause are fatigue, anxiety, irritability, mood swings, insomnia etc. Other symptoms of menopause are dysfunctional uterine bleeding, disturbed sleep pattern and others.

The market drivers for global menopause treatment market are rise in population, increasing awareness regarding women health, development of healthcare and gynaecology centres, and development in drugs especially the advancements in hormonal drugs etc. The market restraints are the complications of drug treatment such as osteoporosis, bleeding, high cost of treatment, etc.

The global menopause treatment market is expected to reach USD 3.3 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.2 % during the forecast period 2017-2023.

Research Methodology
Intended Audience

- Global menopause treatment manufacturers & suppliers
- Research and development (R&D) companies
- Hospitals and clinics
- Academic institutes and universities

Segments

The global menopause treatment market has been segmented on the basis of hormonal treatment, non-hormonal treatment and end user.
Based on the hormonal treatment, the market has been segmented as estrogen, progesterone, combination of the two and other.

Based on the non-hormonal treatment, the market has been segmented as anti-depressants, anti-anxiety, anti-migraine and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.

Regional Analysis
The Americas account for a significant market share owing to high expenditure on the healthcare. Additionally, the fastest uptake of new products in the US drives the menopause treatment market. Furthermore, concentration of the major healthcare companies in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high amount on its healthcare, which accounts for 16% of total GDP, that also increases the sale in menopause treatment market.

Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period. The strong pharmaceutical industry in Germany is a strong driver behind the dominance of this country in Europe.

Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare insurance in the Asia Pacific region is expected to drive the future menopause treatment market in the region.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.

Key Players in the Global Menopause treatment Market
4.6 Technology Trends & Assessment

5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

6. Global Menopause Treatment Market, by Hormonal Treatment
6.1 Introduction
6.2 Estrogen
6.2.1 Market Estimates & Forecast, 2017-2023
6.3 Progesterone
6.3.1 Market Estimates & Forecast, 2017-2023
6.4 Combination
6.4.1 Market Estimates & Forecast, 2017-2023
6.5 Other
6.5.1 Market Estimates & Forecast, 2017-2023

7. Global Menopause Treatment Market, by Non-Hormonal Treatment
7.1 Introduction
7.2 Anti-Depressants
7.2.1 Market Estimates & Forecast, 2017-2023
7.3 Anti-Anxiety
7.3.1 Market Estimates & Forecast, 2017-2023
7.4 Anti-Migrane
7.4.1 Market Estimates & Forecast, 2017-2023
7.4 Others
7.4.1 Market Estimates & Forecast, 2017-2023

8. Global Menopause Treatment Market, by End User
8.1 Introduction
8.2 Hospitals & Clinics
8.2.1 Market Estimates & Forecast, 2017-2023
8.3 Academic and Research Institutes
8.3.1 Market Estimates & Forecast, 2017-2023
8.4 Others
8.4.1 Market Estimates & Forecast, 2017-2023

9. Global Menopause Treatment Market, by Region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 UK
9.3.1.4 Italy
9.3.1.5 Spain
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa

10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

11 Company Profiles
11.1 Merck & Co., Inc.
11.1.1 Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 Key Developments
11.2 Novartis AG
11.2.1 Overview
11.2.2 Product Overview
11.2.3 Financials
11.2.4 Key Developments
11.3 Novo Nordisk A/S
11.3.1 Overview
11.3.2 Product Overview
11.3.3 Financials
11.3.4 Key Development
11.4 Pfizer, Inc.
11.4.1 Overview
11.4.2 Product Overview
11.4.3 Financials
11.4.4 Key Development
11.5 Allergan plc
11.5.1 Overview
11.5.2 Product Overview
11.5.3 Financials
11.5.4 Key Development
11.6 Emcure Pharmaceuticals Ltd.
11.6.1 Overview
11.6.2 Product Overview
11.6.3 Financials
11.6.4 Key Development
11.7 Eli Lilly and Company
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Development
11.8 Cipla Inc.
11.8.1 Overview
11.8.2 Product Overview
11.8.3 Financials
11.8.4 Key Development
11.9 Teva Pharmaceutical Industries Ltd.
11.9.1 Overview
11.9.2 Product Overview
11.9.3 Financials
11.9.4 Key Development
11.10 Others
11.10.1 Overview
11.10.2 Product Overview
11.10.3 Financials
11.10.4 Key Development

12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO's View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Menopause Treatment Industry

13 Appendix

List of Tables

TABLE 1 GLOBAL MENOPAUSE TREATMENT MARKET, BY HORMONAL TREATMENT, 2017-2023 (USD MILLION)
TABLE 2 ESTROGEN FOR MENOPAUSE TREATMENT MARKET, BY REGION, 2017-2023 (USD MILLION)
TABLE 3 PROGESTERONE FOR MENOPAUSE TREATMENT MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 4 COMBINATION FOR MENOPAUSE TREATMENT MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 5 OTHER FOR MENOPAUSE TREATMENT MARKET, BY REGION 2017-2023 (USD MILLION)
TABLE 6 GLOBAL MENOPAUSE TREATMENT MARKET, BY NON-HORMONAL TREATMENT, 2017-2023 (USD MILLION)

Anti-Depressants
Anti-Anxiety
Anti-Migrane

TABLE 7 ANTI-DEPRESSANTS FOR MENOPAUSE TREATMENT MARKET, BY REGION, 2017-2023 (USD MILLION)
TABLE 8 ANTI-ANXIETY FOR MENOPAUSE TREATMENT MARKET, BY REGION 2017-2023 (USD MILLION)
FIGURE 17 PFIZER INC.: GEOGRAPHICAL REVENUE
FIGURE 18 NOVARTIS AG: KEY FINANCIALS
FIGURE 19 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 20 NOVARTIS AG: GEOGRAPHICAL REVENUE
FIGURE 21 NOVO NORDISK A/S: KEY FINANCIALS
FIGURE 22 NOVO NORDISK A/S: SEGMENTAL REVENUE
FIGURE 23 NOVO NORDISK A/S: GEOGRAPHICAL REVENUE
FIGURE 24 ELI LILLY AND COMPANY: KEY FINANCIALS
FIGURE 25 ELI LILLY AND COMPANY: SEGMENTAL REVENUE
FIGURE 26 ELI LILLY AND COMPANY: GEOGRAPHICAL REVENUE
FIGURE 27 ALLERGAN PLC: FINANCIAL REVENUE
FIGURE 28 ALLERGAN PLC: SEGMENTAL REVENUE
FIGURE 29 ALLERGAN PLC: GEOGRAPHICAL REVENUE